Arrowhead's 79%-81% TG Drop Makes ARWR a Regulatory Story Again

SHASTA turned a strong Phase 3 readout into a near-term regulatory catalyst

Arrowhead reported median triglyceride reductions of 79% and 81% in SHASTA-3 and SHASTA-4, versus approximately 27% with placebo. In the highest-risk subgroup-patients with triglycerides above 880 mg/dL and a history of acute pancreatitis-acute pancreatitis events fell by 100%. That matters because the commercial value of a sHTG therapy is not just a lower number on a lab report; it is the potential to reduce severe pancreatitis flare-ups and the hospitalizations that come with them.

Management has described plozasiran's profile as best-in-class on activity, safety, and convenience. The market responded quickly, and the next checkpoint is close: Arrowhead plans to present detailed results on August 30, 2026 and has said it intends to pursue approval before the end of 2026. If those dates hold, ARWR has a short catalyst chain: fuller data first, then filing timing, then commercial comparison with an incumbent.

That said, the strongest data do not settle every question. Without head-to-head results, any best-in-class claim remains preliminary, and review timelines or post-approval adoption could still moderate the upside.

Why this is primarily a label-expansion story

This is not a de novo approval gamble. Plozasiran is approved as Redemplo for FCS, and SHASTA adds data in a much larger sHTG population: around 750 adults with fasting triglycerides of 500 mg/dL or higher. That gives Arrowhead a more direct path to expand an already validated asset into a broader indication, with an sNDA catalyst for severe hypertriglyceridemia already in view.

Market size is now part of the thesis

The space is large enough to matter. Ionis raised TRYNGOLZA peak net sales guidance to >$2B for sHTG after its own approval activity in the indication. That does not guarantee Arrowhead will capture a comparable share, but it does suggest this is a meaningful market rather than a niche side story.

Quarterly dosing is the main differentiator

In SHASTA, patients received 4 doses of 25 mg plozasiran subcutaneously once every three months. For a chronic condition where long-term adherence matters, quarterly dosing is a practical advantage and the clearest competitive wedge against monthly regimens.

That is why the competitive comparison matters. Tryngolza already showed that demand exists in this space, and investors quickly factored that possibility into Arrowhead's shares: ARWR jumped more than 20% to $91.48 at market open on the Phase 3 news.

The real contest is against an approved incumbent

Ionis is no longer a future threat. TRYNGOLZA was approved for sHTG last month, and it reported preliminary 2025 U.S. net product sales of $105M. That shifts the debate from whether a sHTG market exists to how easily a later entrant can take share from a therapy that already has approval and customers.

The stock's post-trial move shows investors see real upside, but not necessarily a settled winner. After the jump, ARWR still traded below the roughly $115 range cited by some market coverage. In other words, the market is rewarding the possibility of a clean regulatory lane, while still leaving room for further rerating if Arrowhead executes on the next milestones.

If the schedule holds, the next 90 days should be decisive. Arrowhead plans to present detailed results on August 30, 2026 and intends to seek FDA approval by year-end. The bull case is that plozasiran reinforces its clinical signal and wins early commercial relevance. The bear case is simpler: once a rival already has approval and sales, late entrants need a clear reason for payers and clinicians to switch habits.